黑色素瘤的联合疗法：一种新的护理标准？
Combination Therapies for Melanoma: A New Standard of Care?
作者信息
Smalley Keiran S M, Eroglu Zeynep, Sondak Vernon K
机构信息
The Department of Cutaneous Oncology, Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL, USA.
The Department of Tumor Biology, Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
出版信息
Am J Clin Dermatol. 2016 Apr;17(2):99-105. doi: 10.1007/s40257-016-0174-8.
Recent data have demonstrated improved survival with targeted and immune therapies in patients with advanced melanoma, leading to much excitement amongst the oncology community and the widespread use of these drugs in combination regimens. However, the place of these combination therapies in the treatment of advanced melanoma remains to be fully determined. In this perspectives article, we critically review the available data and outline the rationale for these combinations being adopted as the standard of care for patients with advanced melanoma in the future.
近期数据显示，靶向治疗和免疫治疗可提高晚期黑色素瘤患者的生存率，这在肿瘤学界引发了极大的兴奋，并促使这些药物在联合治疗方案中得到广泛应用。然而，这些联合治疗在晚期黑色素瘤治疗中的地位仍有待充分确定。在这篇观点文章中，我们批判性地回顾了现有数据，并概述了这些联合治疗在未来被采纳为晚期黑色素瘤患者标准治疗方案的理论依据。
Zotero 插件